63 related articles for article (PubMed ID: 16705943)
1. [Genetic factors and colorectal cancers development: therapeutic impact].
Olschwang S; Viret F; Monges G; Seitz J; Sevenet N; Tiret E; Milano G; Birnbaum D; Bertucci F
Med Sci (Paris); 2006 Jan; 22 Spec No 1():45-9. PubMed ID: 16705943
[TBL] [Abstract][Full Text] [Related]
2. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
3. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
4. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of mitochondrial mutations in colorectal cancer.
Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
[TBL] [Abstract][Full Text] [Related]
6. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
7. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
8. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
10. Evidence for colorectal cancer micrometastases using reverse transcriptase-polymerase chain reaction analysis of MUC2 in lymph nodes.
Bernini A; Spencer M; Frizelle S; Madoff RD; Willmott LD; McCormick SR; Niehans GA; Ho SB; Kratzke RA
Cancer Detect Prev; 2000; 24(1):72-9. PubMed ID: 10757125
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive factors in colorectal cancer.
Zlobec I; Lugli A
J Clin Pathol; 2008 May; 61(5):561-9. PubMed ID: 18326017
[TBL] [Abstract][Full Text] [Related]
12. Retention of chromosome arm 5q in stage II colon cancers identifies 83% of liver metastasis occurrences.
Zeitoun G; Buecher B; Bayer J; Tanguy ML; Thomas G; Olschwang S
Genes Chromosomes Cancer; 2006 Jan; 45(1):94-102. PubMed ID: 16206176
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive factors in colorectal cancer.
Zlobec I; Lugli A
Postgrad Med J; 2008 Aug; 84(994):403-11. PubMed ID: 18832400
[TBL] [Abstract][Full Text] [Related]
15. [Molecular pathology of colorectal cancer].
Bosman FT; Joris F
Rev Med Suisse Romande; 1999 Oct; 119(10):775-82. PubMed ID: 10582488
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
17. Allelic loss of chromosome 18q and prognosis in colorectal cancer.
Jen J; Kim H; Piantadosi S; Liu ZF; Levitt RC; Sistonen P; Kinzler KW; Vogelstein B; Hamilton SR
N Engl J Med; 1994 Jul; 331(4):213-21. PubMed ID: 8015568
[TBL] [Abstract][Full Text] [Related]
18. Aspects of survival from colorectal cancer in Denmark.
Iversen LH
Dan Med J; 2012 Apr; 59(4):B4428. PubMed ID: 22459726
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors affecting survival in stage II colorectal cancer: is lymph node harvesting relevant?
Peeples C; Shellnut J; Wasvary H; Riggs T; Sacksner J
Dis Colon Rectum; 2010 Nov; 53(11):1517-23. PubMed ID: 20940600
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
